Literature DB >> 22253347

Pancreatic endocrine neoplasms: a current update on genetics and imaging.

S Philips1, S N Shah, R Vikram, S Verma, A K P Shanbhogue, S R Prasad.   

Abstract

Pancreatic endocrine neoplasms are rare pancreatic tumours that may occur sporadically or as part of inherited syndromes such as multiple endocrine neoplasia-1 syndrome, von Recklinghausen disease, von Hippel-Lindau syndrome and tuberous sclerosis complex. Recent advances in the genetics and pathology of hereditary syndromes have provided valuable insights into the pathophysiology and biology of sporadic pancreatic endocrine neoplasms. Evolving molecular data on the biology of these neoplasms have the potential for diagnostic, therapeutic and prognostic use.

Entities:  

Mesh:

Year:  2012        PMID: 22253347      PMCID: PMC3474103          DOI: 10.1259/bjr/85014761

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  75 in total

Review 1.  New drugs in neuroendocrine tumors: rising of new therapeutic philosophies?

Authors:  Barbro Eriksson
Journal:  Curr Opin Oncol       Date:  2010-07       Impact factor: 3.645

Review 2.  Neurofibromin: a general outlook.

Authors:  A B Trovó-Marqui; E H Tajara
Journal:  Clin Genet       Date:  2006-07       Impact factor: 4.438

Review 3.  Pancreatic tumours as part of the MEN-1 syndrome.

Authors:  Göran Akerström; Ola Hessman; Per Hellman; Britt Skogseid
Journal:  Best Pract Res Clin Gastroenterol       Date:  2005-10       Impact factor: 3.043

4.  The NF1 tumor suppressor critically regulates TSC2 and mTOR.

Authors:  Cory M Johannessen; Elizabeth E Reczek; Marianne F James; Hilde Brems; Eric Legius; Karen Cichowski
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-03       Impact factor: 11.205

Review 5.  New drug development in digestive neuroendocrine tumors.

Authors:  I Durán; R Salazar; O Casanovas; V Arrazubi; E Vilar; L L Siu; J Yao; J Tabernero
Journal:  Ann Oncol       Date:  2007-02-13       Impact factor: 32.976

Review 6.  Pancreatic glucagonoma with and without syndrome. Immunocytochemical study of 5 tumour cases and review of the literature.

Authors:  E Ruttman; G Klöppel; G Bommer; M Kiehn; P U Heitz
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1980

7.  Malignant pancreatic endocrine tumor in a child with tuberous sclerosis.

Authors:  Paola Francalanci; Francesca Diomedi-Camassei; Cristina Purificato; Filippo Maria Santorelli; Aldo Giannotti; Carlo Dominici; Alessandro Inserra; Renata Boldrini
Journal:  Am J Surg Pathol       Date:  2003-10       Impact factor: 6.394

8.  Differentiation of neuroendocrine tumors from other pancreatic lesions by echo-enhanced power Doppler sonography and somatostatin receptor scintigraphy.

Authors:  S Rickes; K Unkrodt; K Ocran; H Neye; W Wermke
Journal:  Pancreas       Date:  2003-01       Impact factor: 3.327

Review 9.  von Hippel-Lindau disease.

Authors:  Russell R Lonser; Gladys M Glenn; McClellan Walther; Emily Y Chew; Steven K Libutti; W Marston Linehan; Edward H Oldfield
Journal:  Lancet       Date:  2003-06-14       Impact factor: 79.321

Review 10.  Clinical review 72: diagnosis and management of functioning islet cell tumors.

Authors:  R R Perry; A I Vinik
Journal:  J Clin Endocrinol Metab       Date:  1995-08       Impact factor: 5.958

View more
  2 in total

1.  Role of (68)Ga-DOTATATE PET/CT in patients with multiple endocrine neoplasia type 1 (MEN1).

Authors:  Secondo Lastoria; Francesca Marciello; Antongiulio Faggiano; Luigi Aloj; Corradina Caracò; Michela Aurilio; Laura D'Ambrosio; Francesca Di Gennaro; Valeria Ramundo; Luigi Camera; Leonardo De Luca; Rosa Fonti; Vincenzo Napolitano; Annamaria Colao
Journal:  Endocrine       Date:  2015-08-05       Impact factor: 3.633

2.  The added value of intravoxel incoherent motion diffusion weighted imaging parameters in differentiating high-grade pancreatic neuroendocrine neoplasms from pancreatic ductal adenocarcinoma.

Authors:  Wanling Ma; Mengqi Wei; Zhiwei Han; Yongqiang Tang; Qi Pan; Guangwen Zhang; Jing Ren; Yi Huan; Na Li
Journal:  Oncol Lett       Date:  2019-09-13       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.